The greatly misunderstood erythropoietin resistance index and the case for a new responsiveness measure
Authors:
- 3 February 2016
- journal article
- anemia
- Published by Wiley in Hemodialysis International
- Vol. 20 (3) , 392-398
Abstract
Introduction The optimal use of erythropoiesis stimulating agents (ESAs) to treat anemia in end stage renal disease remains controversial due to reported associations with adverse events. In analyzing these associations, studies often utilize ESA resistance indices (ERIs), to characterize a patient's response to ESA. In this study, we examine whether ERI is an adequate measure of ESA resistance. Methods We used retrospective data from a nonconcurrent cohort study of incident hemodialysis patients in the United States (n = 9386). ERI is defined as average weekly erythropoietin (EPO) dose per kg body weight (wt) per average hemoglobin (Hgb), over a 3‐month period (ERI = (EPO/wt)/Hgb). Linear regression was used to demonstrate the relationship between ERI and weight‐adjusted EPO. The coefficient of variation was used to compare the variability of Hgb with that of weight‐adjusted EPO to explain this relationship. This analysis was done for each quarter during the first year of dialysis. Findings ERI is strongly linearly related with weight‐adjusted EPO dose in each of the four quarters by the equation ERI = 0.0899*(EPO/wt) (range of R2 = 0.97–0.98) and weakly linearly related to 1/Hgb (range of R2 = 0.06–0.16). These correlations hold independent of age, sex, hgb level, ERI level, and epo‐naïve stratifications. Discussion ERI is strongly linearly related to weight‐adjusted (and nonweight‐adjusted) EPO dose by a “universal,” not patient‐specific formula, and thus is a surrogate of EPO dose. Therefore, associations between ERI and clinical outcomes are associations between a confounded EPO dose and those outcomes.Keywords
This publication has 30 references indexed in Scilit:
- Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort studyInternational Urology and Nephrology, 2013
- Relationship between erythropoietin resistance index and left ventricular mass and function and cardiovascular events in patients on chronic hemodialysisHemodialysis International, 2011
- Erythropoietic Response and Outcomes in Kidney Disease and Type 2 DiabetesNew England Journal of Medicine, 2010
- A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney DiseaseNew England Journal of Medicine, 2009
- Greater Epoetin alfa (EPO) doses and short‐term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dLPharmacoepidemiology and Drug Safety, 2009
- Greater Epoetin alfa Responsiveness Is Associated With Improved Survival in Hemodialysis PatientsClinical Journal of the American Society of Nephrology, 2008
- Cohort StudiesClinical Journal of the American Society of Nephrology, 2006
- Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietinKidney International, 2005
- Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patientsAmerican Journal of Kidney Diseases, 2003
- Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patientsAmerican Journal of Kidney Diseases, 1999